BDSI

BioDelivery Sciences International, Inc. (BDSI) | Rumor.io

BioDelivery Sciences International

BDSI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BDSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Mar 22

BioDelivery Sciences International, Inc. (BDSI) has filed a Form SC TO-T/A with the SEC regarding a tender offer statement.
Several directors and executives, including Kevin Kotler, W. Mark Watson, James Vollins, and Jeffrey Allen Bailey, have made new insider filings with the SEC.
BDSI has been involved in a delisting from the NYSE, with the company intending to file a certification and notice of termination of registration on Form 15 with the SEC.

Generated by AI

Sentiment

Of the messages about BDSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Feb 15

BioDelivery Sciences International, Inc. (BDSI) has a strong revenue growth YoY of 4.20%, placing it in the top 2852 companies in our database.
The recent buyout of BDSI is a significant event, with the company's market capitalization increasing to over $500 million, making it a valuable asset.
BDSI's current price of $5.60 presents a potential upside for investors, with the possibility of additional buyouts or partnerships that could further increase its value.

Bearish· May 2

$BDSI is stuck in a trading range between $1.85 and $1.99, with many sell orders at $1.90.
The accumulation distribution for $BDSI has just headed lower, indicating a potential decline in the stock.
Investors are expecting $BDSI to go down for the next few days, with some even predicting a significant decline, calling it the "worst stock" they've ever seen.

Generated by AI

Topics

Of the messages about BDSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	100%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Earnings· Nov 8

BioDelivery Sciences International, Inc. (BDSI) reported Q3 2018 earnings with a loss of 10 cents per share and revenue of $14.16 million.
The company beat the Estimize EPS consensus by 2 cents but missed the Estimize revenue consensus by $0.28 million.
BDSI's Q3 earnings call and webcast was held on the scheduled date and time, providing investors with an opportunity to discuss the results.

Analysts· Jun 9

BioDelivery Sciences International's ($BDSI) price target has been raised by several analysts, including Piper Jaffray to $24.00 and Ladenburg Thalmann to $18.00.
Analysts at Laidlaw, William Blair, and Roth Capital have reiterated buy ratings on $BDSI with price targets of $15.00, $23.00, and $15.50, respectively.
Analyst Charles Duncan from Piper Jaffray has a +8.4% average return and has reiterated a buy rating on $BDSI.

Announcements· Mar 22

BioDelivery Sciences International, Inc. (BDSI) has completed its acquisition by Collegium Pharmaceutical, Inc. (COLL).
BDSI's CEO, Jeffrey Allen Bailey, has filed a new insider filing with the SEC, disclosing his ownership stake in the company.
BDSI has been delisted from the exchange, with the company filing a certification and notice of termination of registration with the SEC, requesting the termination of registration.

Technical Analysis· Oct 28

The stochastic indicator is coming off oversold, pointing up, and a bullish reversal hammer formed on the daily chart.
A breach of $5.66 with volume could lead to a move towards $6, with $6-$7 being a possible target.
The stock needs to move up to avoid confirming a downward trend of lower highs, with $5.80 resistance being challenged again.

Generated by AI

Community

Of the messages about BDSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	0%
Newcomers	—	—	100%	100%

Regulars· Mar 22

BioDelivery Sciences International, Inc. (BDSI) has completed its acquisition by Collegium Pharmaceuticals.
There have been several recent insider filings with the SEC, including new filings from directors W. Mark Watson, Kevin Kotler, and Jeffery Allen Bailey, as well as a filing from Chief Medical Officer Thomas B Smith and other insiders.
BDSI's stock price has broken above its higher Bollinger Band, which may indicate a potential drop in price.

Newcomers· Feb 15

BioDelivery Sciences International, Inc. (BDSI) has been downgraded by Piper Sandler from $5.00 to $5.60, indicating a reduced price target.
There is an ongoing investigation by Halper Sadeh LLP into the fairness of the sale of BDSI to its shareholders.
BDSI has shown a notable gain, with a $500 investment 10 days ago being worth $765.84 today, according to the ticker time machine.

Generated by AI

Also Discussed

Investors talking about BDSI also mention

#	Name	Attention
1	MACK - Merrimack Pharmaceuticals, Inc.	——
2	XOMA CorporationXOMA	0%0
3	Celldex Therapeutics IncCLDX	0%+0
4	RDUS - Radius Recycling, Inc.	——
5	EGRX - Eagle Pharmaceuticals, Inc.	——
6	FOLD - Amicus Therapeutics, Inc.	——
7	Ironwood Pharmaceuticals, Inc. Class A Common StockIRWD	0%new
8	Acadia Pharmaceuticals Inc.ACAD	0%+0
9	PTC Therapeutics, Inc.PTCT	0%new
10	Exelixis Inc.EXEL	0%-0.03